Clinical Impact of New Data From Boston 2016
Source: Clinical Impact of New Hepatology Data From Boston 2016*

Conference Program

 

Slideset

Clinical Impact of New Data From Boston 2016

In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 542 KB
Date posted: 11/30/2016
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C

    Mark S. Sulkowski MD - 9/15/2015    14 comments / Last Comment: 6/25/2016
    Using a recent case patient, I outline my current approach to using HCV resistance testing to select therapy in patients who have previously received an HCV NS5A inhibitor.
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015    2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016    6 comments / Last Comment: 6/25/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.